DE68915675D1 - Verfahren zur Reinigung von Vitamin K-abhängigen Proteinen. - Google Patents

Verfahren zur Reinigung von Vitamin K-abhängigen Proteinen.

Info

Publication number
DE68915675D1
DE68915675D1 DE68915675T DE68915675T DE68915675D1 DE 68915675 D1 DE68915675 D1 DE 68915675D1 DE 68915675 T DE68915675 T DE 68915675T DE 68915675 T DE68915675 T DE 68915675T DE 68915675 D1 DE68915675 D1 DE 68915675D1
Authority
DE
Germany
Prior art keywords
vitamin
proteins
purification
dependent proteins
culture medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE68915675T
Other languages
English (en)
Other versions
DE68915675T3 (de
DE68915675T2 (de
Inventor
Sau-Chi Betty Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26943089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE68915675(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE68915675D1 publication Critical patent/DE68915675D1/de
Publication of DE68915675T2 publication Critical patent/DE68915675T2/de
Publication of DE68915675T3 publication Critical patent/DE68915675T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6478—Aspartic endopeptidases (3.4.23)
    • C12N9/6481—Pepsins (3.4.23.1; 3.4.23.2; 3.4.23.3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Enzymes And Modification Thereof (AREA)
DE68915675T 1988-10-04 1989-10-02 Verfahren zur Reinigung von Vitamin K-abhängigen Proteinen. Expired - Lifetime DE68915675T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25327988A 1988-10-04 1988-10-04
US07/393,281 US4981952A (en) 1988-10-04 1989-08-16 Method for the purification of vitamin K-dependent proteins

Publications (3)

Publication Number Publication Date
DE68915675D1 true DE68915675D1 (de) 1994-07-07
DE68915675T2 DE68915675T2 (de) 1994-10-20
DE68915675T3 DE68915675T3 (de) 2002-08-14

Family

ID=26943089

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68915675T Expired - Lifetime DE68915675T3 (de) 1988-10-04 1989-10-02 Verfahren zur Reinigung von Vitamin K-abhängigen Proteinen.

Country Status (13)

Country Link
US (1) US4981952A (de)
EP (1) EP0363126B2 (de)
JP (1) JP2848461B2 (de)
KR (1) KR0139209B1 (de)
AT (1) ATE106406T1 (de)
AU (1) AU635222B2 (de)
CA (1) CA1314011C (de)
DE (1) DE68915675T3 (de)
DK (1) DK176090B1 (de)
ES (1) ES2054019T5 (de)
HU (1) HU204538B (de)
IE (1) IE63765B1 (de)
IL (1) IL91822A (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8729822D0 (en) * 1987-12-22 1988-02-03 Central Blood Lab Authority Chemical process
DE3833936C1 (de) * 1988-10-05 1989-09-21 Henning Berlin Gmbh Chemie- Und Pharmawerk, 1000 Berlin, De
DE3911629A1 (de) * 1989-04-10 1990-10-11 Behringwerke Ag Verfahren zur abtrennung von toxinen aus proteinloesungen
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
AU671586B2 (en) 1991-03-01 1996-09-05 Aventis Behring Llc Preparation of factor IX
IT1262899B (it) * 1992-03-27 1996-07-22 Sclavo Spa Processo per l'isolamento di fattore ix, fattore x e fattore ii altamente purificati dal complesso protrombinico o dal plasma umano
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DK38293D0 (da) * 1993-03-31 1993-03-31 Novo Nordisk As Fremstilling af proteiner
US5618714A (en) * 1993-12-15 1997-04-08 Eli Lilly And Company Methods for producing protein C
DE4406515C1 (de) * 1994-02-28 1995-10-19 Immuno Ag Verfahren zur Isolierung und Reinigung Vitamin K-abhängiger Proteine
DE4435520A1 (de) * 1994-10-04 1996-04-11 Immuno Ag Verfahren zur Trennung von rekombinantem pro-Faktor IX von rekombinantem Faktor IX
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
US5869604A (en) * 1995-11-09 1999-02-09 Georgia Institute Of Technology Crystallization and purification of polypeptides
US5910584A (en) * 1996-09-05 1999-06-08 Asahi Kogaku Kogyo Kabushiki Kaisha Method for isolating plasmid DNA
US5843731A (en) * 1996-09-05 1998-12-01 Asahi Kogaku Kogyo Kabushiki Kaisha Method for purifying plasmid DNA on calcium phosphate compound
EP1557463A1 (de) * 1997-04-28 2005-07-27 Eli Lilly & Company Verbesserte Methoden zur Verarbeitung von aktiviertem Protein C
BR9809304B1 (pt) * 1997-04-28 2011-02-08 formulação liofilizada estável, processo para preparação da mesma, bem como forma de dosagem unitária.
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
CA2293429A1 (en) * 1997-06-05 1998-12-10 Eli Lilly And Company Methods for treating thrombotic disorders
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
IL142248A0 (en) 1998-10-22 2002-03-10 Lilly Co Eli Methods for treating sepsis
IL142255A0 (en) 1998-11-13 2002-03-10 Lilly Co Eli Method of treating heparin-induced thrombocytopenia
ES2195655T3 (es) 1998-11-20 2003-12-01 Lilly Co Eli Procedimiento para tratar fiebre hemorragica virica con proteina c.
AU1723200A (en) 1998-11-23 2000-06-13 Eli Lilly And Company Method of treating sickle cell disease and thalassemia
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
WO2001089558A2 (en) 2000-05-24 2001-11-29 Eli Lilly And Company Formulations and use of activated protein c and protein c zymogen for treating hypercoagulable states
US6869934B2 (en) * 2000-07-21 2005-03-22 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method of purifying calcium ion-binding protein
WO2002085117A1 (en) * 2001-04-24 2002-10-31 Eisai Co., Ltd. Methods and compositions for preventing and treating septic shock and endotoxemia
WO2003007686A2 (en) * 2001-07-19 2003-01-30 Dmi Biosciences, Inc. Use of copper chelators to inhibit the inactivation of protein c
JP4628618B2 (ja) * 2001-09-26 2011-02-09 富士フイルム株式会社 撮像光学系
AU2003213146A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Activated protein c formulations
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
EP1651252B1 (de) * 2003-07-08 2014-11-26 The Scripps Research Institute Aktivierte protein c varianten mit normaler zytoprotektiver aktivität aber verringerter gerinnungshemmender aktivität
US9192657B2 (en) * 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
EP1773371A4 (de) * 2004-07-23 2009-12-30 Univ Rochester Aktiviertes protein c hemmt unerwünschte effekte von plasminogenaktivator im gehirn
EP1831242B1 (de) 2004-12-23 2012-09-26 Novo Nordisk Health Care AG Reduktion des gehaltes an kontaminierenden proteinen in zusammensetzungen, die vitamin k-abhängige proteine von interesse umfassen
US20090047723A1 (en) * 2005-01-14 2009-02-19 Bayer Healthcare Llc Method for purification of factor vii
US8088728B2 (en) * 2005-06-24 2012-01-03 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory tract
WO2007071767A1 (en) * 2005-12-23 2007-06-28 Novo Nordisk Health Care Ag Purification of vitamin k-dependent polypeptides using preparative reverse phase chromatography (rpc)
TWI428448B (zh) 2006-03-24 2014-03-01 Syntonix Pharmaceuticals Inc 作為第九因子（ｆａｃｔｏｒ ｉｘ）原肽處理酶之ｐｃ５
WO2008073603A2 (en) * 2006-10-31 2008-06-19 The Scripps Research Institute Dosing regimen of activated protein c and variants having reduced anticoagulant activity
EP2125866B1 (de) 2007-02-28 2013-05-22 Baxter International Inc. Verfahren zur reinigung von mit sulfatierten und/oder phosphorylierten molekülen angereichtem rekombinantem blutgerinnungsfaktor ix
AU2008245524A1 (en) 2007-04-26 2008-11-06 Cnj Holdings, Inc. Recombinant vitamin K dependent proteins with high sialic acid content and methods of preparing same
HUE037633T2 (hu) 2007-07-09 2018-09-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
US20110287518A1 (en) 2008-12-02 2011-11-24 Novo Nordisk Health Care A/G Polypeptide Purification
CN102325880B (zh) 2008-12-19 2014-10-01 国家健康与医学研究院 丝氨酸蛋白酶衍生物及其在凝血功能障碍的预防或治疗中的用途
EP2199387A1 (de) 2008-12-19 2010-06-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Serinproteasederivate und deren Verwendung zur Vorbeugung und/oder Behandlung von Blutgerinnungsstörungen
WO2011053738A1 (en) 2009-10-30 2011-05-05 Inspiration Biopharmaceuticals, Inc. Method of producing recombinant vitamin k dependent proteins
US9896677B2 (en) 2010-01-18 2018-02-20 Novo Nordisk Health Care Ag Purification of blood coagulation factors
NZ603289A (en) * 2010-04-29 2014-07-25 Baxter Int Purification method for divalent cation binding proteins on anion exchange resin
ES2784628T3 (es) 2011-03-29 2020-09-29 Glaxosmithkline Llc Sistema de tampón para purificación de proteína
AU2012304763A1 (en) 2011-09-06 2014-03-06 Medimmune Llc Methods for processing coagulation factors
WO2013053888A1 (en) * 2011-10-14 2013-04-18 Baxter International Inc. Protein purification by anion exchange chromatography
LT2748179T (lt) * 2011-10-14 2022-04-11 Takeda Pharmaceutical Company Limited Baltymų gryninimas anijonų mainų chromatografija
US20150150954A1 (en) 2012-07-04 2015-06-04 The University Of Sydney Treatment of inflammatory skin disorders
DK2970376T3 (en) * 2013-03-15 2018-07-02 Baxalta Inc PURIFICATION PROCEDURE FOR VITAMIN K-DEPENDENT PROTEINS BY ANION EXCHANGE CHROMATOGRAPHY
AU2014391082B2 (en) 2014-04-16 2020-04-09 Zz Biotech Llc Treatment of abnormal cutaneous scarring
CA3009458A1 (en) * 2016-01-07 2017-07-13 Eio Biomedical Ltd Methods, compositions and kits for reducing tissue adhesions

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4512992A (en) * 1980-06-13 1985-04-23 Burroughs Wellcome Co. Treatment with dialkoxy pyridopyrimidine compounds
DE3101752A1 (de) * 1981-01-21 1982-08-26 Behringwerke Ag, 3550 Marburg "verfahren zur reinigung der blutgerinnungsfaktoren ii, vii, ix und/oder x und danach hergestellte praeparationen"
US4518526A (en) * 1982-12-22 1985-05-21 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4599197A (en) * 1982-12-22 1986-07-08 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4766224A (en) * 1985-08-19 1988-08-23 International Minerals & Chemical Corp. Purification and activation of proteins from insoluble inclusion bodies
US4677196A (en) * 1985-09-06 1987-06-30 International Minerals & Chemical Corp. Purification and activation of proteins from insoluble inclusion bodies
US4786726A (en) * 1986-01-06 1988-11-22 Blood Systems, Inc. Factor IX therapeutic blood product, means and methods of preparing same
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
DE3615558A1 (de) * 1986-05-09 1987-11-12 Behringwerke Ag Verfahren zur herstellung eines faktor v-konzentrats

Also Published As

Publication number Publication date
HUT53373A (en) 1990-10-28
KR0139209B1 (ko) 1998-04-30
DK485589A (da) 1990-04-05
DK176090B1 (da) 2006-05-22
IL91822A (en) 2001-06-14
EP0363126B2 (de) 2002-03-06
IE893159L (en) 1990-04-04
EP0363126A2 (de) 1990-04-11
IL91822A0 (en) 1990-06-10
US4981952A (en) 1991-01-01
EP0363126A3 (de) 1991-09-11
KR900006511A (ko) 1990-05-08
JPH02200180A (ja) 1990-08-08
ES2054019T5 (es) 2002-10-16
IE63765B1 (en) 1995-06-14
DE68915675T3 (de) 2002-08-14
DE68915675T2 (de) 1994-10-20
JP2848461B2 (ja) 1999-01-20
AU635222B2 (en) 1993-03-18
ES2054019T3 (es) 1994-08-01
HU204538B (en) 1992-01-28
DK485589D0 (da) 1989-10-03
EP0363126B1 (de) 1994-06-01
ATE106406T1 (de) 1994-06-15
CA1314011C (en) 1993-03-02
AU4251989A (en) 1990-04-12

Similar Documents

Publication Publication Date Title
DE68915675D1 (de) Verfahren zur Reinigung von Vitamin K-abhängigen Proteinen.
ATE200293T1 (de) Verfahren zur chromatographischen reinigung und trennung von nucleinsäuregemischen
DE69907439D1 (de) Reinigung von proteinen durch ionenaustauschchromatographie
ES8100502A1 (es) Un procedimiento para purificar proteinas con pesos moleculares superiores a 12.000,en particular interferon
DE68923115D1 (de) Reinigung von Hepatitis-Proteinen.
DK0460426T3 (da) Fremgangsmåde til proteinrensning
ATE124703T1 (de) Verfahren zur trennung von proteinen.
ATE154033T1 (de) Verfahren zur reinigung von proteinen
FI103974B1 (fi) Menetelmä proteiinin puhdistamiseksi
KR900003207A (ko) 트롬빈 결합성 물질 및 이의 제조방법
BR8108074A (pt) Sequencia de dna,plasmidio recombinante,ligadores de dna,cultura bacterial e processo para produzir taumatina
ATE20540T1 (de) Vollsynthetisches zellkulturmedium.
ATE166062T1 (de) Verfahren zur reinigung des big-endothelin proteins
ATE135402T1 (de) Reinigung von erwinia-l-asparaginase
DE3788170D1 (de) Methode zur Reinigung und Isolierung von zwei ionischen Formen von Somatomedin.
DE69530261D1 (de) Durch Zelldichte stimulierte Protein-Tyrosin-Phosphatasen
ATE76082T1 (de) Reinigungsmethode fuer antikoerper.
Ruff et al. Glycoprotein Proteinase in Agkistrodon bilineatus Venom
DE69637278D1 (de) Methode zur herstellung von thrombin
DE3783425D1 (de) Mikroorganismen, die fremdproteinenthaltende pili tragen, isolierte pili, verfahren zur ausscheidung von proteinen in verwendung dieser pili und deren nutzen.
KR880001805A (ko) 조 임파구 인터페론의 정제방법
KR920012426A (ko) 인간 표피 성장 인자의 정제방법
KR920012436A (ko) 인간 인슐린 유사 성장인자-i의 정제 방법

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings